Hims & Hers Health (NYSE:HIMS) Lowered to Neutral Rating by BTIG Research

BTIG Research downgraded shares of Hims & Hers Health (NYSE:HIMS) from a buy rating to a neutral rating in a research note released on Tuesday, MarketBeat reports.

Several other brokerages have also commented on HIMS. Zacks Research lowered shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. UBS Group set a $32.00 price target on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Hims & Hers Health and gave the stock a “hold” rating in a report on Tuesday, February 10th. Evercore assumed coverage on Hims & Hers Health in a research report on Monday, January 12th. They set an “in-line” rating and a $33.00 price objective on the stock. Finally, Citigroup reduced their target price on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating on the stock in a report on Monday, February 9th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and a consensus price target of $32.27.

Hims & Hers Health Trading Down 0.5%

NYSE HIMS opened at $15.43 on Tuesday. The stock has a market cap of $3.51 billion, a P/E ratio of 30.26, a price-to-earnings-growth ratio of 2.90 and a beta of 2.43. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock has a 50 day simple moving average of $27.79 and a two-hundred day simple moving average of $39.76. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.25% and a net margin of 5.47%.The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the company earned $0.11 earnings per share. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. On average, analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its board has approved a stock repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 82,963 shares of company stock valued at $2,944,621. Insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of Hims & Hers Health by 0.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock valued at $1,452,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC grew its position in Hims & Hers Health by 6.1% during the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock valued at $232,000 after purchasing an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in Hims & Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock valued at $793,000 after purchasing an additional 252 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Beat on EPS and subscriber growth — HIMS reported Q4 revenue up ~28% YoY and an EPS beat while saying subscribers have crossed 2.5 million, showing demand resilience. Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
• Positive Sentiment: Acquisition and 2026 revenue guidance provide upside potential — Management projects 2026 revenue of $2.7–$2.9B (above some estimates) and highlighted the Eucalyptus acquisition as an incremental revenue driver. Hims & Hers forecasts 2026 revenue above estimates
• Positive Sentiment: Bullish analyst/features note long‑term growth path — Bullish writeups highlight multi‑year international expansion, Eucalyptus’ contribution and a path to much larger revenue/EBITDA over time. Hims & Hers Health: Don’t Get Lost In The Weeds
• Neutral Sentiment: Unusual options activity — Heavy call buying was reported, which can indicate speculative bullish interest but is not definitive on fundamentals.
• Negative Sentiment: Soft near‑term guidance and margin pressure — Q1 revenue guidance came in below street estimates and margins showed contraction, prompting investor concern about short‑term growth and profitability. Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
• Negative Sentiment: Regulatory and SEC scrutiny — The company disclosed an SEC probe and management addressed scrutiny over compounding of GLP‑1 products, raising legal and operational risk for its core weight‑loss business. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
• Negative Sentiment: Analyst downgrades and price‑target cuts — Several firms trimmed forecasts and ratings (Citigroup cut its target to $13.25 with a sell), increasing near‑term sell pressure. Analyst price target and rating actions

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.